13 June 2022 - - UK-based synthetic biology company Evonetix LTD has appointed Colin McCracken as chief executive officer with immediate effect, the company said.

Colin's appointment will support the next phase of the company's development and the commercialisation of its semiconductor-based DNA synthesis platform.

Colin brings over 20 years' experience in commercial and business development roles.

Prior to joining Evonetix he was senior vice president and chief commercial officer at Fluidigm Corp, where he was responsible for leading all commercial activities, driving revenue growth, and expanding the company's global reach.

He has delivered commercial success in numerous leadership positions, including vice president and general manager and vice president of sales at Thermo Fisher Scientific (NYSE: TMO), vice president and Head of European Sales at Life Technologies and National Sales Manager at Qiagen.

As CEO of Evonetix, Colin will focus on building strategic partnerships and customer relationships, ahead of the commercial introduction of the company's first product, a benchtop DNA printer.

The announcement comes as Evonetix continues to strengthen its senior leadership team, following the recent appointment of Paul Beastall as chair, as the company enters the next phase of its development, moving from pure research and development into product commercialisation.